Testosterone

Diagnosis and treatment of polycystic ovary syndrome (PCOS) using virtual health

By Dr. Caitlin Dunne on November 30, 2022

Polycystic ovary syndrome is the most common endocrinopathy in women of reproductive age. It affects 8%–13% of young women and its symptoms are some of the most prevalent concerns that community physicians encounter. In many cases, diagnosis and management can be carried out in a virtual health setting using clinical criteria and judicious use of laboratory investigations.

Minimal evidence of benefit from medications to increase sexual desire

By Dr. Rosemary Basson on May 21, 2014

Aside from testosterone replacement to younger men with proven testosterone deficiency, evidence of benefit from hormonal or pharmacological therapy to increase sexual desire is minimal.

When vulvovaginal atrophy involves loss of genital sexual sensitivity: local (vaginal) dehydroepiandrosterone (DHEA) shows promise

By Dr. Rosemary Basson on December 3, 2013

Recent studies have shown that the local delivery of the main precursor hormone of testosterone and estrogen, dehydroepiandrosterone (DHEA) effectively treats dyspareunia and dryness from VVA and does not increase serum levels of estrogen and testosterone.

Don’t request testosterone levels for women’s low sexual desire

By Dr. Rosemary Basson on August 15, 2011

Although men with repeatedly low serum testosterone levels typically have low sexual desire, no such link has been identified in women.

Testosterone

Diagnosis and treatment of polycystic ovary syndrome (PCOS) using virtual health

Minimal evidence of benefit from medications to increase sexual desire

When vulvovaginal atrophy involves loss of genital sexual sensitivity: local (vaginal) dehydroepiandrosterone (DHEA) shows promise

Don’t request testosterone levels for women’s low sexual desire

Recent Articles

Recent Comments

Visit UBC CPD at ubccpd.ca